# US 8,465,775 B2 · Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,775 B2
- Document ID: US8465775B2
- Status: Granted
- Kind: B2
- Application number: 12/374,182
- Filed: 2007-07-27
- Published: 2010-02-04
- Granted: 2013-06-18
- Earliest claimed: 2006-07-27
- Assignees: The University of North Carolina at Chapel Hill
- Applicants: Joseph M. DeSimone; Edward T. Samulski
- Inventors: Joseph M. DeSimone; Edward T. Samulski
- Web page: https://patentgrep.com/patent/US8465775B2

## CPC

- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A61K 38/1703: {from vertebrates}
- A61K 38/42: Haemoglobins; Myoglobins
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 μm.

## Claims

### Claim 1

An artificial red blood cell comprising a substantially disc shaped, molded synthetic polymer particle having a largest linear dimension of between about 5 um to about 10 um and a modulus of less than about 1 MPa; and wherein the particle can pass through a tube having an inner diameter of less than about 3 um.

### Claim 2 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle has a largest linear dimension of about 8 μm.

### Claim 3 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle has a volume of about 98 μm3.

### Claim 4 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle has a surface area of about 130 μm2.

### Claim 5 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle is hydrophilic.

### Claim 6 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle comprises poly(ethylene glycol).

### Claim 7 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle comprises perfluoropolyether.

### Claim 8 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle further comprises surface functionality selected from the group consisting of PEGylation, blood type antigens, and natural mimics.

### Claim 9 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle further comprises a cargo selected from the group consisting of a therapeutic agent, hemoglobin, or an imaging agent.

### Claim 10 (depends on 1)

The artificial red blood cell of claim 1, wherein said particle further comprises a cargo and the cargo is capable of binding and releasing oxygen.